secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2022-02-17T23:59:59+00:00
Accession:  0001559053-22-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena reports FY2021 net income of $67M; cash $580M; pipeline advances with SPA and partnerships
--------------------------------------------------------------------------------

- FY2021 revenue $200.6M (vs $0.9M in 2020); net income $67.0M vs net loss $111.1M in 2020.
- Cash and restricted cash $580.4M at Dec 31, 2021, no debt; raised $175M in equity in 2021.
- Received $80M BMS option for PRX005, $60M Roche milestone for prasinezumab, $60M upfront from Novo Nordisk for ATTR.
- Reached SPA agreement with FDA for confirmatory Phase 3 AFFIRM-AL study of birtamimab in AL amyloidosis; Phase 1 of PRX005 initiated.
- 2022 guidance: net cash used $120-132M; expected net loss $154-170M; ending cash ~$454M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905322000003/0001559053-22-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905322000003/prta-20220217.htm
  HTML page:      https://secwatch.observer/filing/0001559053-22-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer